Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01810237|
Recruitment Status : Withdrawn (No patients recruited)
First Posted : March 13, 2013
Last Update Posted : January 31, 2017
Nova Scotia Health Authority
Information provided by (Responsible Party):
Sudeep Shivakumar, Nova Scotia Health Authority
- Does using dabigatran bridging result in consistent therapeutic anticoagulation? What percentage of patients will become subtherapeutic on warfarin once dabigatran is stopped?
- What is the incidence of bleeding events with the use of dabigatran overlapped with warfarin for bridging?
- What is the cost benefit of using dabigatran instead of dalteparin for bridging anticoagulation?
|Condition or disease||Intervention/treatment||Phase|
|Venous Thromboses||Drug: Dabigatran.||Not Applicable|
Show detailed description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||September 2013|
|Experimental: Dabigtran instead of LMWH for perioperative bridging.||
Dabigatran will be used instead of LMWH for anticoagulation bridging.
Primary Outcome Measures :
- Validation of a novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy [ Time Frame: 1 Year. ]
No Contacts or Locations Provided